Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Burixafor for DTC Mobilization in Metastatic Prostate Cancer
NCT02478125Phase 1Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jul 2016
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of burixafor in prostate cancer (PCa), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Jul 2016; status: terminated.
02
Drugs
burixafor
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02478125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02478125.